Spero Sells Portion of Utebzi Economics for $105M to Fuel SP001 Development

Spero Therapeutics monetizes its Utebzi royalty stream in a $105M non-dilutive financing deal with Healthcare Royalty, extending cash runway to 2H 2029 while funding SP001 development.